Core Viewpoint - The Hang Seng Index Company announced the results of the quarterly review for the Hang Seng Index series, with Valiant Bio-B (09887) being included in the Hang Seng Composite Index, effective from March 9, 2026 [1] Group 1: Company Updates - Valiant Bio-B is likely to be included in the Stock Connect program due to meeting various criteria such as market capitalization, liquidity, and listing duration [1] - The company announced that the first patient has successfully received treatment in the Phase Ib/II clinical trial of its PD-L1/4-1BB bispecific antibody, Opalizumab (LBL-024), for recurrent or metastatic triple-negative breast cancer [1] - The open-label, multicenter Phase Ib/II clinical study is led by Professor Yin Yongmei from Jiangsu Provincial People's Hospital and is being conducted simultaneously at multiple hospitals across the country [1] Group 2: Clinical Research - The trial aims to evaluate the efficacy and safety of Opalizumab administered alone or in combination with albumin-bound paclitaxel in patients with recurrent or metastatic triple-negative breast cancer [1]
维立志博-B(09887)获纳入恒生综合指数 有望成为港股通标的